Utility of Integrated PET/MRI for the Primary Diagnostic Work-Up of Patients with Ewing Sarcoma: Preliminary Results.
Ewing sarcoma
PET/MRI
staging
treatment monitoring
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
21 Sep 2022
21 Sep 2022
Historique:
received:
16
08
2022
revised:
15
09
2022
accepted:
16
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
This study was conducted to evaluate the clinical applicability of integrated PET/MRI for staging and monitoring the effectiveness of neoadjuvant chemotherapy in Ewing sarcoma patients. A total of 11 juvenile patients with confirmed Ewing sarcoma, scheduled for induction polychemotherapy, were prospectively enrolled for a PET/MR examination before, during and after the end of treatment. Two experienced physicians analysed the imaging datasets. They were asked to perform a whole-body staging in all three examinations and to define treatment response according to the RECIST1.1 and PERCIST criteria for each patient. In eight patients lymph node and/or distant metastases were detected at initial diagnosis. According to the reference standard, three patients achieved complete response, six patients partial response, and one patient showed stable disease while another patient showed progressive disease. RECIST1.1 categorized the response to treatment in 5/11 patients correctly and showed a tendency to underestimate the response to treatment in the remaining six patients. PERCIST defined response to treatment in 9/11 patients correctly and misclassified two patients with a PR as CR. PET/MRI may serve as a valuable imaging tool for primary staging and response assessment of juvenile patients with Ewing sarcoma to induction chemotherapy, accompanied by a reasonable radiation dose for the patient.
Sections du résumé
BACKGROUND
BACKGROUND
This study was conducted to evaluate the clinical applicability of integrated PET/MRI for staging and monitoring the effectiveness of neoadjuvant chemotherapy in Ewing sarcoma patients.
METHODS
METHODS
A total of 11 juvenile patients with confirmed Ewing sarcoma, scheduled for induction polychemotherapy, were prospectively enrolled for a PET/MR examination before, during and after the end of treatment. Two experienced physicians analysed the imaging datasets. They were asked to perform a whole-body staging in all three examinations and to define treatment response according to the RECIST1.1 and PERCIST criteria for each patient.
RESULTS
RESULTS
In eight patients lymph node and/or distant metastases were detected at initial diagnosis. According to the reference standard, three patients achieved complete response, six patients partial response, and one patient showed stable disease while another patient showed progressive disease. RECIST1.1 categorized the response to treatment in 5/11 patients correctly and showed a tendency to underestimate the response to treatment in the remaining six patients. PERCIST defined response to treatment in 9/11 patients correctly and misclassified two patients with a PR as CR.
CONCLUSION
CONCLUSIONS
PET/MRI may serve as a valuable imaging tool for primary staging and response assessment of juvenile patients with Ewing sarcoma to induction chemotherapy, accompanied by a reasonable radiation dose for the patient.
Identifiants
pubmed: 36291967
pii: diagnostics12102278
doi: 10.3390/diagnostics12102278
pmc: PMC9600118
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Nucl Med. 2019 Nov;60(11):1537-1542
pubmed: 30926647
Eur J Radiol. 2015 Nov;84(11):2097-102
pubmed: 26321491
Ann Surg Oncol. 2010 Oct;17(10):2578-84
pubmed: 20556523
Ann Surg Oncol. 2012 Oct;19(11):3375-85
pubmed: 22622472
Radiology. 2003 Nov;229(2):526-33
pubmed: 14512512
Pediatr Blood Cancer. 2022 Mar;69(3):e29415
pubmed: 34709700
J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30
pubmed: 18525458
J Nucl Med. 2016 Apr;57(4):582-6
pubmed: 26742715
Pediatr Hematol Oncol. 2012 Feb;29(1):1-11
pubmed: 22295994
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
Clin Cancer Res. 2008 Feb 1;14(3):715-20
pubmed: 18245531
Eur J Nucl Med. 2000 Sep;27(9):1305-11
pubmed: 11007511
Case Rep Med. 2013;2013:791078
pubmed: 24368921
J Nucl Med. 2016 May;57(5):735-40
pubmed: 26795289
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Nucl Med. 2010 Mar;51(3):333-6
pubmed: 20150252
Clin Nucl Med. 2000 Nov;25(11):874-81
pubmed: 11079583
J Clin Oncol. 2007 Dec 1;25(34):5435-41
pubmed: 18048826
Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27
pubmed: 12829150
Ann Oncol. 2021 Dec;32(12):1520-1536
pubmed: 34500044
Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1814-24
pubmed: 26199113
Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1842-53
pubmed: 20505933
Medicine (Baltimore). 2018 Nov;97(48):e13457
pubmed: 30508968
J Nucl Med. 2008 Oct;49(10):1579-84
pubmed: 18794268
J Nucl Med. 2007 Dec;48(12):1932-9
pubmed: 18006618
J Nucl Med. 2021 Mar;62(3):348-353
pubmed: 32737246
J Natl Compr Canc Netw. 2017 Feb;15(2):155-167
pubmed: 28188186
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1976-1986
pubmed: 33415433
Radiology. 2014 Oct;273(1):220-31
pubmed: 24877983
Sarcoma. 2010;2010:143540
pubmed: 20414348